CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity

© The Author(s) 2019.

Bibliographic Details
Authors: Bueno, Clara, Velasco-Hernández, Talia, Gutiérrez-Agüera, Francisco, Zanetti, Samanta Romina, Baroni, Matteo L., Sánchez-Martínez, Diego, Molina, Oscar, Closa, Adria, Agraz-Doblas, Antonio, Marín, Pedro, Eyras, Eduardo, Varela, Ignacio, Menéndez, Pablo
Format: article
Status:Published version
Publication Date:2019
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/220030
Online Access:http://hdl.handle.net/10261/220030
Access Level:Open access
Keyword:Acute lymphocytic leukaemia
Immunotherapy
id ES_80a2337b1dd28cbb509aed6e2cc135bb
oai_identifier_str oai:digital.csic.es:10261/220030
network_acronym_str ES
network_name_str España
repository_id_str
spelling CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicityBueno, ClaraVelasco-Hernández, TaliaGutiérrez-Agüera, FranciscoZanetti, Samanta RominaBaroni, Matteo L.Sánchez-Martínez, DiegoMolina, OscarClosa, AdriaAgraz-Doblas, AntonioMarín, PedroEyras, EduardoVarela, IgnacioMenéndez, PabloAcute lymphocytic leukaemiaImmunotherapy© The Author(s) 2019.Chimeric antigen receptors (CARs) have undoubtedly revolutionized immunotherapy, especially in the B-cell acute lymphoblastic leukemia (ALL) arena where over 80% of complete remissions are observed in refractory/relapsed (R/R) B-cell ALL patients treated with CD19-directed CAR T-cells (CARTs) [1]. However, despite holding an unprecedented promise, several issues still have to be resolved before CARTs can be expanded to novel targets and/or malignancies or even provided as first-line treatment in Bcell ALL [2]. For instance, toxicities such as cytokine release syndrome and immune escape mechanisms including loss of the antigen under CART-mediated pressure remain major concerns, urging further research on the mechanisms underlying CARTs cytotoxicity.This work has been supported by the European Research Council (CoG-2014-646903, PoC-2018-811220) to PM, the Spanish Ministry of Economy and Competitiveness (MINECO, SAF-SAF2016-80481-R, BIO2017-85364-R) to PM and EE, the Generalitat de Catalunya (SGR330, SGR102 and PERIS) to PM and EE, the Spanish Association against cancer (AECC-CI-2015) to CB, and the Health Institute Carlos III (ISCIII/FEDER, PI14-01191) to CB. PM also acknowledges financial support from the Obra Social La Caixa-Fundaciò Josep Carreras. SRZ and TV are supported by a Marie Curie fellowships. OM is supported by the Catalan Government through a Beatriu de Pinos fellowship. MB is supported by MINECO through a PhD scholarship. PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).Peer reviewedSpringer NatureEuropean Research CouncilMinisterio de Economía y Competitividad (España)Generalitat de CatalunyaAsociación Española Contra el CáncerInstituto de Salud Carlos IIIFundación la CaixaConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202020202019info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/220030reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2016-80481-Rinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BIO2017-85364-Rhttps://doi.org/10.1038/s41375-019-0418-8Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2200302026-05-22T06:33:51Z
dc.title.none.fl_str_mv CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
title CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
spellingShingle CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
Bueno, Clara
Acute lymphocytic leukaemia
Immunotherapy
title_short CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
title_full CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
title_fullStr CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
title_full_unstemmed CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
title_sort CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
dc.creator.none.fl_str_mv Bueno, Clara
Velasco-Hernández, Talia
Gutiérrez-Agüera, Francisco
Zanetti, Samanta Romina
Baroni, Matteo L.
Sánchez-Martínez, Diego
Molina, Oscar
Closa, Adria
Agraz-Doblas, Antonio
Marín, Pedro
Eyras, Eduardo
Varela, Ignacio
Menéndez, Pablo
author Bueno, Clara
author_facet Bueno, Clara
Velasco-Hernández, Talia
Gutiérrez-Agüera, Francisco
Zanetti, Samanta Romina
Baroni, Matteo L.
Sánchez-Martínez, Diego
Molina, Oscar
Closa, Adria
Agraz-Doblas, Antonio
Marín, Pedro
Eyras, Eduardo
Varela, Ignacio
Menéndez, Pablo
author_role author
author2 Velasco-Hernández, Talia
Gutiérrez-Agüera, Francisco
Zanetti, Samanta Romina
Baroni, Matteo L.
Sánchez-Martínez, Diego
Molina, Oscar
Closa, Adria
Agraz-Doblas, Antonio
Marín, Pedro
Eyras, Eduardo
Varela, Ignacio
Menéndez, Pablo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv European Research Council
Ministerio de Economía y Competitividad (España)
Generalitat de Catalunya
Asociación Española Contra el Cáncer
Instituto de Salud Carlos III
Fundación la Caixa
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Acute lymphocytic leukaemia
Immunotherapy
topic Acute lymphocytic leukaemia
Immunotherapy
description © The Author(s) 2019.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/220030
url http://hdl.handle.net/10261/220030
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2016-80481-R
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BIO2017-85364-R
https://doi.org/10.1038/s41375-019-0418-8
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411912905654272
score 15,812429

Similar Items